OTC Markets OTCPK - Delayed Quote USD

Merck KGaA (MKGAF)

139.70

-1.35

(-0.96%)

At close: May 7 at 3:56:21 PM EDT

MKKGY vs. ZTS: Which Stock Is the Better Value Option?

MKKGY vs. ZTS: Which Stock Is the Better Value Option?

Zacks 6 days ago

ZTS

MRK.DE
Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 6 days ago

MRK.DE
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE:MRK) for $47 per share in cash. The acquisition price translates to an equity value of around $3.9 billion and an enterprise value of $3.4 billion (3.0 billion euros), based on SpringWorks' cash position of $461.9 million as of December 31, 2024. As per media reports in February, Merck Germany reacted to press reports and confirmed advanced

Benzinga 9 days ago

MRK

MRK.DE
Merck KGaA to Buy Springworks for $3.9B

German pharma company Merck is buying US biotech SpringWorks Therapeutics for $3.9B. SpringWorks makes medicines for cancer and rare diseases and is expected to give a boost to Merck's health-care division. Belen Garijo, Merck KGaA CEO joined Bloomberg Open Interest to talk about the deal.

Bloomberg 9 days ago

MRK.DE
Temu, Tesla prices, Merck KGaA deal: Trending Tickers

Online retailer Temu — owned by PDD Holdings (PDD) — aims to raise prices amid tariffs, while Tesla (TSLA) raises its EV prices in Canada and Merck KGaA (MRK) seeks to acquire SpringWorks Therapeutics (SWTX) in a $3.9 billion deal. Catalysts host Madison Mills and Ritholtz Wealth Management chief market strategist Callie Cox weigh in on these top stocks. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.

Yahoo Finance Video 9 days ago

MKGAF
-0.96%

MKKGY

TSLA
5 Things to Know Before the Stock Market Opens

News of the day for April 28, 2025

Investopedia 9 days ago

MRK.DE

DLVEY

AAPL
Merck KGaA strikes $3.9bn deal for SpringWorks

The deal follows months of market speculation and gives Merck access to two FDA-approved therapies.

Pharmaceutical Technology 9 days ago

MRK.DE

GLDAF
Merck KGaA to buy biotech SpringWorks for $3.9B

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

BioPharma Dive 9 days ago

MRK.DE
Germany’s Merck Set to Buy SpringWorks in $3.9 Billion Deal

Germany’s Merck agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business.

The Wall Street Journal 9 days ago

SWTX

MKGAF
-0.96%

MKKGY
Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments.

Investopedia 9 days ago

MRK.DE
SpringWorks Therapeutics to Be Acquired by Germany's Merck in $3.9 Billion Deal

SpringWorks Therapeutics (SWTX) stock rose early Monday after the biopharmaceutical company agreed t

PREMIUM
MT Newswires 9 days ago

MRK.DE
Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents. The deal came at a price tag about 20% lower than what analysts expected due to lack of other serious bidders and the overall devaluation of the U.S. biotech sector. Policy and regulatory changes for the healthcare sector in the United States, including massive layoffs at the U.S. Food and Drug Administration that approves new drugs, have been stalling large life science deals in what had been expected to be a stellar year for mergers and acquisitions.

Reuters 10 days ago

MRK.DE
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business – – SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for

GlobeNewswire 10 days ago

MKGAF
-0.96%

MKKGY

SWTX
Merck KGaA nears $3.5bn deal for SpringWorks

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per share.

Pharmaceutical Technology 12 days ago

MRK.DE

GLDAF
Merck KGaA (ETR:MRK) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

It looks like Merck KGaA ( ETR:MRK ) is about to go ex-dividend in the next 2 days. The ex-dividend date is two...

Simply Wall St. 13 days ago

MKGAF
-0.96%

MKKGY
Germany’s Merck Nears Roughly $3.5 Billion Deal for SpringWorks

Germany’s Merck KGaA is finally nearing a roughly $3.5 billion deal for SpringWorks Therapeutics a U.S. biopharmaceutical company that specializes in rare diseases and cancer. The two parties are discussing a deal around $47 per share, Merck said in a statement Thursday, confirming an earlier report in The Wall Street Journal. Merck said no final agreement had been made.

The Wall Street Journal 13 days ago

SWTX

MKGAF
-0.96%

MKKGY
SpringWorks Therapeutics springs higher as Merck KGaA takeover said close

Investing.com -- Shares of SpringWorks Therapeutics Inc (NASDAQ:SWTX) surged higher Thursday afternoon on reports that a potential takeover of the company by Germany’s Merck KGaA (ETR:MRCG) is getting close.

Investing.com 13 days ago

MRK.DE
Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access to a recently approved rare disease drug and expand its portfolio of experimental cancer treatments. Merck said that the companies are in discussions on the basis of a price of around $47 per share, which gives a valuation of roughly $3.5 billion, according to Reuters calculations. No final decision has been taken and no legally binding agreement has been entered into, Merck said in a statement.

Reuters 13 days ago

MRK.DE
Are Investors Undervaluing Merck KGaA (ETR:MRK) By 49%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Merck KGaA fair value estimate is €239 Merck KGaA's €121 share...

Simply Wall St. 14 days ago

MKGAF
-0.96%

MKKGY
There May Be Some Bright Spots In Merck KGaA's (ETR:MRK) Earnings

Shareholders appeared unconcerned with Merck KGaA's ( ETR:MRK ) lackluster earnings report last week. We did some...

Simply Wall St. last month

MKGAF
-0.96%

MKKGY

Performance Overview

Return	MKGAF	DAX P (^GDAXI)
YTD	-3.08%	+17.29%
1-Year	-17.23%	+26.23%
3-Year	-17.20%	+70.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Merck KGaA (MKGAF)

MKKGY vs. ZTS: Which Stock Is the Better Value Option?

Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?

Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion

Merck KGaA to Buy Springworks for $3.9B

Temu, Tesla prices, Merck KGaA deal: Trending Tickers

5 Things to Know Before the Stock Market Opens

Merck KGaA strikes $3.9bn deal for SpringWorks

Merck KGaA to buy biotech SpringWorks for $3.9B

Germany’s Merck Set to Buy SpringWorks in $3.9 Billion Deal

Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

SpringWorks Therapeutics to Be Acquired by Germany's Merck in $3.9 Billion Deal

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Merck KGaA nears $3.5bn deal for SpringWorks

Merck KGaA (ETR:MRK) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Germany’s Merck Nears Roughly $3.5 Billion Deal for SpringWorks

SpringWorks Therapeutics springs higher as Merck KGaA takeover said close

Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion

Are Investors Undervaluing Merck KGaA (ETR:MRK) By 49%?

There May Be Some Bright Spots In Merck KGaA's (ETR:MRK) Earnings

Performance Overview